ArticleFrontiers in pharmacology2026
Mechanistic investigation of Midkine-Notch2 signaling in suppressing pulmonary artery smooth muscle cell apoptosis and promoting vascular remodeling in hypoxic pulmonary hypertension.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypoxic pulmonary hypertension (HPH), a severe complication of chronic obstructive pulmonary disease, features pulmonary vascular remodeling driven by dysregulated pulmonary arterial smooth muscle cell (PASMC) apoptosis, with limited therapies like vasodilators offering only modest hemodynamic benefits. This study aimed to elucidate the role of Midkine (MK) in regulating PASMC apoptosis via the Notch2 pathway and its potential as a novel anti-remodeling target in HPH progression. Methods: The experimental approach involved cellular and animal models. Results: Conclusion: Unlike current vasodilators, MK drives HPH pathogenesis by suppressing PASMC apoptosis via Notch2 and exacerbating oxidative stress. Targeting MK offers a promising therapeutic strategy for HPH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.